Plus Therapeutics
PSTV
6 hedge funds and large institutions have $118K invested in Plus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
81% less capital invested
Capital invested by funds: $609K → $118K (-$491K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$127K |
| 2 |
Barclays
London,
United Kingdom
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$182K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$88.8K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$59K |
| 4 |
VF
Virtu Financial
New York
|
-$34K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $81K | +$127K | +10 | +1,000% |
|
|
PCM
2
Perkins Capital Management
Wayzata,
Minnesota
| $10K | -$88.8K | -7 | -88% |
|
3
BlackRock
New York
| $10K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $6K | – | – | – |
|
|
5
Barclays
London,
United Kingdom
| $5K | +$12.7K | +1 | New |
|
|
MOS
6
MGO One Seven
Beachwood,
Ohio
| $4K | +$12.7K | +1 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $5 | – | – | – |
|
|
10
Vanguard Group
Malvern,
Pennsylvania
| – | -$182K | -7 | Closed |
|
|
11
Dimensional Fund Advisors
Austin,
Texas
| – | -$59K | -2 | Closed |
|
|
12
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$29K | -2 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$34K | -1 | Closed |
|
PSTV Hedge Fund Activity: Q3 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2018, worth a combined $118K — down 81% from $609K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PSTV and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $127K. The largest seller was Vanguard Group, exiting entirely with an estimated $182K sold.
- 6 institutional investors held Plus Therapeutics (PSTV) as of Q3 2018, down from 8 in Q2 2018.
- Funds reported $118K of Plus Therapeutics stock for Q3 2018, down 81% quarter-over-quarter.
- 2 funds opened new Plus Therapeutics positions in Q3 2018 and 4 closed out, a net change of -2 holders.
- The largest Plus Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $127K added.
- The largest Plus Therapeutics seller in Q3 2018 was Vanguard Group, an estimated $182K sold.
Based on aggregated 13F filings for Q3 2018.